Genflow Biosciences Share Discussion Threads

[moneymunch] 26/6/2024 15:16

Publication Number WO/2024/121363

Publication Date 13.06.2024

International Application No. PCT/EP2023/084840

International Filing Date 08.12.2023

[moneymunch] 26/6/2024 15:12

Another ( latest ) patent application. Gla ;-)



3.WO/2024/121363

VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

WO - 13.06.2024

Int.Class A61K 38/43 Appl.No PCT/EP2023/084840 Applicant GENFLOW BIOSCIENCES SRL Inventor VINCIGUERRA, Manlio

The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease.

[moneymunch] 26/6/2024 14:58

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,651 followers
2h

A recent survey reveals that many Americans prefer a shorter, healthier life over a longer one burdened by diseases that impact their quality of life. But what if modern medicine could offer both longevity and health?

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s dedicated team of experienced researchers is at the forefront of the medical industry, working tirelessly to turn this possibility into a reality. We are committed to developing solutions that promise a longer and healthier life for everyone.

Read more here:

#GENF #aging #healthspan #longevity

[moneymunch] 24/6/2024 10:58

Looks like share accumulation on the cheap...they want your shares imho... Big news at anytime and the next UPdate must be very close. Gla holders. :-)

[northeast14] 20/6/2024 07:13

Hopefully we get a transformational update soon.
GLA

[moneymunch] 18/6/2024 19:07

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,643 followers
6h

While advanced anti-aging treatments are on the horizon, The Economist has researched ways humans can extend their #healthspan presently. Italian scientist Valter Longo has sworn by fasting for years after learning about its benefits during his time at the USC Longevity Institute.

While lifestyle choices significantly impact #longevity, emerging treatments also promise enhanced and extended quality of life.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) works with the #centenarian variant of the #SIRT6 gene, which has been correlated with a longer lifespan. This groundbreaking work has the potential to revolutionize how we treat a number of aging related diseases.

Read the article here:

#longevity #aging #GENF

[moneymunch] 15/6/2024 11:49

News Release 14-Jun-2024

Announcing Longevity Science Foundation as tier 5 sponsor of ARDD 2024

Empowering the future of aging research: Longevity Science Foundation to sponsor ARDD 2024, the world's largest conference on aging research in the biopharmaceutical industry

Business Announcement

Aging Research and Drug Discovery

The University of Copenhagen is excited to announce Longevity Science Foundation as a Tier 5 Sponsor of the 11th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 26 - August 30, 2024 on-site at the Ceremonial Hall, University of Copenhagen, and online.

..........

ARDD 2024 is set to feature a stellar lineup. The Longevity Science Foundation, along with esteemed academic institutions, clinicians, industry leaders, investors, and pharmaceutical companies, will contribute to rich dialogues and present new research in the field of aging. This year, ARDD is proud to be a partner of XPRIZE Healthspan, a 7-year, $101 million global competition to revolutionize the way we approach human aging. Highlighting this collaboration, XPRIZE Healthspan will host its first XPRIZE Healthspan Team Summit at the 11th ARDD. The event underscores a shared commitment between ARDD and XPRIZE to fostering advancements in health and longevity, signaling an important milestone in efforts to enable everyone to live healthier and longer lives through extended healthspan.

“I’m extremely excited about this year's ARDD. We have a stellar academic lineup and an incredibly strong presence from leading companies in the aging field. This year the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and many others have been strengthened and we are super excited that XPRIZE will host their XPRIZE Healthspan Team Summit at ARDD.

[moneymunch] 12/6/2024 07:12

12 June 2024



Genflow Biosciences Plc



Receipt of Grant Funding



Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce receipt of €395,847 representing 50% of the Exofastrack research grant from the Government of Wallonia in Belgium's Advanced Therapy Medicinal Products (ATMPs).



The grant, a non-dilutive, non-reimbursable subsidy, supports Genflow and EXO Biologics' 3-year scientific program. Covering 80% of the expenses, the grant will be used for working capital. The program (see press release here) will deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, an accelerated aging disease.



Dr. Eric Leire, CEO of Genflow commented: "We are thrilled to receive this grant from the Government of Wallonia. This funding will significantly advance our research program focused on exosome-based therapies, potentially leading to groundbreaking treatments for liver fibrosis and Werner Syndrome. Our commitment to pioneering therapeutic solutions for longevity is further strengthened by this support, and we look forward to the impactful developments that will emerge from this collaboration."

[moneymunch] 11/6/2024 13:28

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,633 followers
56m

A recent Prevention article pointed to daily exercise and a diet high in fruits & vegetables as ways to increase your #lifespan.

These measures do offer moderate improvements, yet #biotech research promises a much more significant extension. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) promising #SIRT6 research is an example of research conducted that could combat aging and its symptoms.

Coupled with our growing IP portfolio, it’s no wonder The Guardian named us a firm to watch in 2024!

Read the Prevention article to learn how to extend your #healthspan in the meantime:

#aging #healthspan #GENF

[moneymunch] 10/6/2024 16:37

Plenty of chunky trades under the radar, looks like the share accumulation continues. Gla holders...Big news at anytime!!! ;-)

[moneymunch] 07/6/2024 08:38

News on Monday from Eric would be very timely. Gla holders:-)


10th - 11th June 2024 - Organised by Longevity Technology who hold 3% of Genflow, the advisory panel includes Eric Verdin who sits on Genflow's Scientific Advisory Board, Aubrey de Grey who originally was a member of Genflow's SAB and Jim Mellon who was an investor in Genflow's IPO....All bodes well!!! Gla ;-)


New international event program launches to bring longevity entrepreneurs and investors together.

Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.

[moneymunch] 06/6/2024 17:21

Cheap shares accumulated, the big players continue to mop up the few shares in free float....Gla holders, they want your shares!!! :-)

Ps those hoping to get back in sub 3p are going to be greatly disappointed i reckon , with news at anytime getting closer and closer. ...On and UP!!! :-)

[moneymunch] 05/6/2024 17:52

Highly relevant and exciting for the prospects and potential of Genflow's AAV gene therapy R&D. Gla :-)



In a First, AAV-Based Gene Therapy Restores Hearing in Both Ears of Children with Hereditary Deafness.

5/6/24

[moneymunch] 05/6/2024 10:31

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,623 followers

16h

Aging is not only a societal challenge but also an #economic one. As the number of Americans over the age of 65 rises, so do the costs associated with healthcare.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is filled with committed researchers who are working to lighten aging's financial burden.

#GENF offers:
↗️ research focusing on #centenarian variant of the #SIRT6 gene
↗️ promising, innovative treatments for a variety of illnesses
↗️ scientific advisory board is filled with dedicated & committed researchers

Make sure to take a look at National Library of Medicines take on the economic implications of aging :

#aging #healthspan

[moneymunch] 05/6/2024 08:47

Perfectly poised and primed, as the spring becomes coiled in anticipation of the next UPdate and significant move North. Gla holders:-)

[moneymunch] 04/6/2024 07:19

Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board.

Exponential upside potential and prospects!!!

Will a Major Pharma/JV partner wait for positive trial results from Genflow's Nash Human Clinical Phase 1/2 trials planned for next year, or will one move early given how hot the Nash/Liver space is right now, as well as the promise of a rapidly expanding and evolving longevity market and the compelling nature of SIRT6's profound importance and influence over multiple disease targets associated with aging.

Big news could at anytime, and any in time for next weeks event would certainly put Genflow centre stage.


10th - 11th June 2024 - Organised by Longevity Technology who hold 3% of Genflow, the advisory panel includes Eric Verdin who sits on Genflow's Scientific Advisory Board, Aubrey de Grey who originally was a member of Genflow's SAB and Jim Mellon who was an investor in Genflow's IPO....All bodes well!!! Gla ;-)


New international event program launches to bring longevity entrepreneurs and investors together.

Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.

The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.

Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.

“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”

Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.

The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.

“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.

“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”

“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.

“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”

[felchandbart] 03/6/2024 08:20

Looks like we have forward momentum again. Would be great to see us back over 4p this week.

[moneymunch] 03/6/2024 07:04

RNS Number : 7241Q
Genflow Biosciences PLC
03 June 2024




3 June 2024

Genflow Biosciences Plc

Notice of Annual General Meeting

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 12pm on Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.

The Notice of the AGM ("Notice") and 2024 Form of Proxy will shortly be available on the Company's website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.

As announced on 7 May 2024, the Company's Annual Report and Accounts for the year ended 31 December 2023 are also available on the website and has, where applicable, also been posted to registered shareholders.

[marmiesz] 02/6/2024 18:08

I'm not expecting any announcement because of the conference. It would be highly unusual to do this and make a presentation although Vera is speaking tonight so it would t be breaking any market rules, I think. Anyhow, no rns and some will sell on no news. Good luck to them, but I'm here for the long haul.Marmie

[moneymunch] 01/6/2024 17:52

The conference starts tomorrow and so it would be amazing to get news on Monday, although regardless, I'm still sure June will see a significant re-rate as important news is delivered. Gla :')

"focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research"

[moneymunch] 01/6/2024 07:57

Maybe incoming news at next weeks conference from Vera's SIRT6 studies at University of Rochester. Gla ;-)

Systems Modeling, Aging Biomarkers, and Longevity Interventions


Systems Aging Gordon Research Conference


June 2 - 7, 2024

The Systems Aging GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages.



Keynote Session: Molecular Approaches in Age Reversal Research

Discussion Leader: Vera Gorbunova (University of Rochester, United States)

[moneymunch] 31/5/2024 13:14

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,618 followers
1d

For the first time since 2020, US life expectancy has increased.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is dedicated to ensuring that #healthspan grows alongside lifespan. Our groundbreaking research surrounding #SIRT6 mutations could revolutionize how we age and ensure we live healthier for longer.

Learn more about our research:

[moneymunch] 31/5/2024 13:12

I reckon we're going to see a decent re-rate this coming month on the back of important news and so I'd be surprised at anything sub 3p going forward...Big players are accumulating for big things to come and every chance of US institutional investors awaiting in the wings...Genflow's prospects and potential suggest the journey from small cap to mid cap is well underway. Gla :-)

[moneymunch] 31/5/2024 10:57

Early stage UK Biotech M & A on the rise. Gla:-)

Genetic Engineering & Biotechnology News

Merck to Acquire UK Biotech EyeBio for Up to $3B, Re-Entering Eye Drug Space

May 29, 2024

Merck & Co. has agreed to acquire EyeBiotech (EyeBio) for up to $3 billion, the companies said today, in a deal that will return the buyer to the eye drug development segment it vacated about a decade ago.

Based in London, EyeBio has developed a pipeline of clinical and preclinical candidates designed to prevent and treat vision loss associated with retinal vascular leakage. EyeBio’s lead candidate Restoret™ (EYE103) is a tetravalent, tri-specific antibody agonist of the Wingless-related integration site (Wnt) signaling pathway.

[marmiesz] 30/5/2024 14:21

Please check your facts bri15. GENF is not an AIM stock.Marmie